Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387444889> ?p ?o ?g. }
- W4387444889 abstract "MR1 : ESGE recommends the following standards for Barrett esophagus (BE) surveillance:- a minimum of 1-minute inspection time per cm of BE length during a surveillance endoscopy- photodocumentation of landmarks, the BE segment including one picture per cm of BE length, and the esophagogastric junction in retroflexed position, and any visible lesions- use of the Prague and (for visible lesions) Paris classification- collection of biopsies from all visible abnormalities (if present), followed by random four-quadrant biopsies for every 2-cm BE length.Strong recommendation, weak quality of evidence. MR2: ESGE suggests varying surveillance intervals for different BE lengths. For BE with a maximum extent of ≥ 1 cm and < 3 cm, BE surveillance should be repeated every 5 years. For BE with a maximum extent of ≥ 3 cm and < 10 cm, the interval for endoscopic surveillance should be 3 years. Patients with BE with a maximum extent of ≥ 10 cm should be referred to a BE expert center for surveillance endoscopies. For patients with an irregular Z-line/columnar-lined esophagus of < 1 cm, no routine biopsies or endoscopic surveillance are advised.Weak recommendation, low quality of evidence. MR3: ESGE suggests that, if a patient has reached 75 years of age at the time of the last surveillance endoscopy and/or the patient's life expectancy is less than 5 years, the discontinuation of further surveillance endoscopies can be considered. Weak recommendation, very low quality of evidence. MR4: ESGE recommends offering endoscopic eradication therapy using ablation to patients with BE and low grade dysplasia (LGD) on at least two separate endoscopies, both confirmed by a second experienced pathologist.Strong recommendation, high level of evidence. MR5: ESGE recommends endoscopic ablation treatment for BE with confirmed high grade dysplasia (HGD) without visible lesions, to prevent progression to invasive cancer.Strong recommendation, high level of evidence. MR6: ESGE recommends offering complete eradication of all remaining Barrett epithelium by ablation after endoscopic resection of visible abnormalities containing any degree of dysplasia or esophageal adenocarcinoma (EAC).Strong recommendation, moderate quality of evidence. MR7: ESGE recommends endoscopic resection as curative treatment for T1a Barrett's cancer with well/moderate differentiation and no signs of lymphovascular invasion.Strong recommendation, high level of evidence. MR8: ESGE suggests that low risk submucosal (T1b) EAC (i. e. submucosal invasion depth ≤ 500 µm AND no [lympho]vascular invasion AND no poor tumor differentiation) can be treated by endoscopic resection, provided that adequate follow-up with gastroscopy, endoscopic ultrasound (EUS), and computed tomography (CT)/positrion emission tomography-computed tomography (PET-CT) is performed in expert centers.Weak recommendation, low quality of evidence. MR9: ESGE suggests that submucosal (T1b) esophageal adenocarcinoma with deep submucosal invasion (tumor invasion > 500 µm into the submucosa), and/or (lympho)vascular invasion, and/or a poor tumor differentiation should be considered high risk. Complete staging and consideration of additional treatments (chemotherapy and/or radiotherapy and/or surgery) or strict endoscopic follow-up should be undertaken on an individual basis in a multidisciplinary discussion.Strong recommendation, low quality of evidence. MR10 A: ESGE recommends that the first endoscopic follow-up after successful endoscopic eradication therapy (EET) of BE is performed in an expert center.Strong recommendation, very low quality of evidence. B: ESGE recommends careful inspection of the neo-squamocolumnar junction and neo-squamous epithelium with high definition white-light endoscopy and virtual chromoendoscopy during post-EET surveillance, to detect recurrent dysplasia.Strong recommendation, very low level of evidence. C: ESGE recommends against routine four-quadrant biopsies of neo-squamous epithelium after successful EET of BE.Strong recommendation, low level of evidence. D: ESGE suggests, after successful EET, obtaining four-quadrant random biopsies just distal to a normal-appearing neo-squamocolumnar junction to detect dysplasia in the absence of visible lesions.Weak recommendation, low level of evidence. E: ESGE recommends targeted biopsies are obtained where there is a suspicion of recurrent BE in the tubular esophagus, or where there are visible lesions suspicious for dysplasia.Strong recommendation, very low level of evidence. MR11: After successful EET, ESGE recommends the following surveillance intervals:- For patients with a baseline diagnosis of HGD or EAC:at 1, 2, 3, 4, 5, 7, and 10 years after last treatment, after which surveillance may be stopped.- For patients with a baseline diagnosis of LGD:at 1, 3, and 5 years after last treatment, after which surveillance may be stopped.Strong recommendation, low quality of evidence." @default.
- W4387444889 created "2023-10-10" @default.
- W4387444889 creator A5001288732 @default.
- W4387444889 creator A5003597455 @default.
- W4387444889 creator A5006745990 @default.
- W4387444889 creator A5006955204 @default.
- W4387444889 creator A5012512364 @default.
- W4387444889 creator A5014360454 @default.
- W4387444889 creator A5021757265 @default.
- W4387444889 creator A5024569726 @default.
- W4387444889 creator A5025381238 @default.
- W4387444889 creator A5027998283 @default.
- W4387444889 creator A5050348689 @default.
- W4387444889 creator A5063206275 @default.
- W4387444889 creator A5075832254 @default.
- W4387444889 creator A5080069752 @default.
- W4387444889 creator A5082207699 @default.
- W4387444889 creator A5083327329 @default.
- W4387444889 creator A5084885160 @default.
- W4387444889 creator A5085229958 @default.
- W4387444889 creator A5086048140 @default.
- W4387444889 creator A5087036759 @default.
- W4387444889 date "2023-10-09" @default.
- W4387444889 modified "2023-10-18" @default.
- W4387444889 title "Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline" @default.
- W4387444889 cites W1247968195 @default.
- W4387444889 cites W1500800749 @default.
- W4387444889 cites W1567900071 @default.
- W4387444889 cites W1568407910 @default.
- W4387444889 cites W1851649310 @default.
- W4387444889 cites W1861545296 @default.
- W4387444889 cites W1964803683 @default.
- W4387444889 cites W1967729236 @default.
- W4387444889 cites W1968695780 @default.
- W4387444889 cites W1976242831 @default.
- W4387444889 cites W1984060133 @default.
- W4387444889 cites W1987652016 @default.
- W4387444889 cites W1989995256 @default.
- W4387444889 cites W1996252264 @default.
- W4387444889 cites W2005305170 @default.
- W4387444889 cites W2005982125 @default.
- W4387444889 cites W2006336028 @default.
- W4387444889 cites W2006601155 @default.
- W4387444889 cites W2007592179 @default.
- W4387444889 cites W2010068380 @default.
- W4387444889 cites W2015889452 @default.
- W4387444889 cites W2024880286 @default.
- W4387444889 cites W2026688865 @default.
- W4387444889 cites W2030162709 @default.
- W4387444889 cites W2032294676 @default.
- W4387444889 cites W2036194723 @default.
- W4387444889 cites W2044866639 @default.
- W4387444889 cites W2051570610 @default.
- W4387444889 cites W2052113971 @default.
- W4387444889 cites W2052478842 @default.
- W4387444889 cites W2056381253 @default.
- W4387444889 cites W2059549380 @default.
- W4387444889 cites W2070256294 @default.
- W4387444889 cites W2071716454 @default.
- W4387444889 cites W2071721969 @default.
- W4387444889 cites W2075195121 @default.
- W4387444889 cites W2097053898 @default.
- W4387444889 cites W2098414153 @default.
- W4387444889 cites W2098511302 @default.
- W4387444889 cites W2100446918 @default.
- W4387444889 cites W2101235315 @default.
- W4387444889 cites W2102632921 @default.
- W4387444889 cites W2111393977 @default.
- W4387444889 cites W2113155618 @default.
- W4387444889 cites W2117910394 @default.
- W4387444889 cites W2120450267 @default.
- W4387444889 cites W2121758465 @default.
- W4387444889 cites W2129797859 @default.
- W4387444889 cites W2130939549 @default.
- W4387444889 cites W2139975606 @default.
- W4387444889 cites W2149491624 @default.
- W4387444889 cites W2156662092 @default.
- W4387444889 cites W2157985041 @default.
- W4387444889 cites W2158612442 @default.
- W4387444889 cites W2159594443 @default.
- W4387444889 cites W2161179649 @default.
- W4387444889 cites W2161840081 @default.
- W4387444889 cites W2162096543 @default.
- W4387444889 cites W2173609033 @default.
- W4387444889 cites W2255421964 @default.
- W4387444889 cites W2316590095 @default.
- W4387444889 cites W2341842346 @default.
- W4387444889 cites W2467382619 @default.
- W4387444889 cites W2507222688 @default.
- W4387444889 cites W2521115864 @default.
- W4387444889 cites W2530286535 @default.
- W4387444889 cites W2561888888 @default.
- W4387444889 cites W2562884120 @default.
- W4387444889 cites W2570454533 @default.
- W4387444889 cites W2581415326 @default.
- W4387444889 cites W2588030422 @default.
- W4387444889 cites W2590699118 @default.
- W4387444889 cites W2602573041 @default.
- W4387444889 cites W2606827827 @default.
- W4387444889 cites W2621353671 @default.